Prader-Willi syndrome due to translocation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:177907OMIM:176270Q87.1
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Prader-Willi syndrome due to translocation (Orphanet code 177907) is a rare genetic subtype of Prader-Willi syndrome (PWS) caused by a chromosomal translocation involving the 15q11-q13 region. This translocation disrupts or leads to loss of function of paternally expressed genes in the PWS critical region on chromosome 15, producing the same clinical phenotype as other genetic mechanisms of PWS. Like all forms of Prader-Willi syndrome, this condition is characterized by severe neonatal hypotonia and feeding difficulties in infancy, followed by the development of hyperphagia (excessive appetite) and progressive obesity beginning in early childhood if caloric intake is not carefully managed. The syndrome affects multiple body systems. Key features include short stature due to growth hormone deficiency, hypogonadism leading to incomplete pubertal development and infertility, mild to moderate intellectual disability, behavioral problems (including temper tantrums, stubbornness, and obsessive-compulsive tendencies), and characteristic facial features such as a narrow forehead, almond-shaped eyes, and a thin upper lip. Individuals may also have small hands and feet, scoliosis, and sleep disturbances including obstructive sleep apnea. Management of Prader-Willi syndrome due to translocation follows the same multidisciplinary approach used for all forms of PWS. Growth hormone therapy is a standard treatment that improves height, body composition, and muscle tone. Strict dietary supervision and environmental food controls are essential to prevent life-threatening obesity. Additional interventions include sex hormone replacement therapy, behavioral management, speech and occupational therapy, and monitoring for complications such as type 2 diabetes, scoliosis, and sleep-disordered breathing. The translocation mechanism is rare among PWS cases, with the majority caused by paternal deletion or maternal uniparental disomy. Genetic counseling is important, as the recurrence risk may differ from other PWS subtypes depending on the specific translocation involved.

Clinical phenotype terms— hover any for plain English:

Weak cryHP:0001612
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Prader-Willi syndrome due to translocation.

View clinical trials →

No actively recruiting trials found for Prader-Willi syndrome due to translocation at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Prader-Willi syndrome due to translocation community →

No specialists are currently listed for Prader-Willi syndrome due to translocation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Prader-Willi syndrome due to translocation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Prader-Willi syndrome due to translocationForum →

No community posts yet. Be the first to share your experience with Prader-Willi syndrome due to translocation.

Start the conversation →

Latest news about Prader-Willi syndrome due to translocation

No recent news articles for Prader-Willi syndrome due to translocation.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Prader-Willi syndrome due to translocation

What is Prader-Willi syndrome due to translocation?

Prader-Willi syndrome due to translocation (Orphanet code 177907) is a rare genetic subtype of Prader-Willi syndrome (PWS) caused by a chromosomal translocation involving the 15q11-q13 region. This translocation disrupts or leads to loss of function of paternally expressed genes in the PWS critical region on chromosome 15, producing the same clinical phenotype as other genetic mechanisms of PWS. Like all forms of Prader-Willi syndrome, this condition is characterized by severe neonatal hypotonia and feeding difficulties in infancy, followed by the development of hyperphagia (excessive appetite

At what age does Prader-Willi syndrome due to translocation typically begin?

Typical onset of Prader-Willi syndrome due to translocation is neonatal. Age of onset can vary across affected individuals.